Deep brain stimulation, including adaptive DBS

1. Introduction

Version followed: US regulatory labelling and manufacturer safety information (Medtronic Reclaim DBS for OCD, Important Safety Information marked Rev 02/22; Medtronic BrainSense Adaptive DBS approval reported February 2025), the Mayo Clinic patient description of DBS, the Tourette DBS selection recommendations as summarised by Xu et al. (2020), and the post-DBS CBT augmentation study of Mantione et al. (2014). Regulatory status checked October 2026 against the sources listed; product status can change, so re-check before quoting it to a client.

Deep brain stimulation (DBS) is a neurosurgical treatment in which thin wires (leads) carrying electrodes are implanted into a specific brain region and connected to a pulse generator placed under the skin of the chest; the generator sends electrical pulses to modulate the activity of the targeted circuit. It is not a psychotherapy and is never delivered by a psychotherapist: it is selected, implanted and programmed by a specialist team (neurology, functional neurosurgery, and, for psychiatric indications, psychiatry, with neuropsychology and other disciplines involved in assessment) [source: Mayo Clinic; Xu et al. 2020]. Adaptive (closed-loop) DBS adds sensing: the system detects and classifies brain signals and adjusts stimulation automatically to the person's changing state [source: AJMC Feb 2025]. DBS is not a cure; symptoms are reduced but usually not abolished, and if stimulation stops, symptoms are likely to return [source: Mayo Clinic; Medtronic OCD risks page]. The core idea of change is circuit-level: stimulation alters the activity of a dysfunctional network, which can lower symptom intensity enough for the person to rebuild functioning, and, in OCD, may make psychological treatment such as exposure with response prevention more workable [source: Mantione et al. 2014 abstract].

This guide is for the psychotherapist working alongside the treating team. Your role is psychological: psychoeducation, supporting informed consent and realistic expectations, contributing (with consent) to the published psychiatric and psychosocial parts of candidate assessment, monitoring and passing on mood and behaviour changes, crisis and safety planning, supporting the client and family through identity and adjustment changes, and integrating psychotherapy after implantation. Nothing here describes stimulation settings, programming or surgical targeting; brain regions are named only as the sources name them.

2. Framework

Regulatory status by indication (as of October 2026, per the sources)

EU/UK: the sources do not give CE-marking or NICE status by indication [uncertain]; Medtronic runs UK patient pages for OCD DBS, which are not drawn on. Coverage policies differ from regulatory status: the BSW policy, for example, lists no OCD diagnosis code among covered codes [source: BSW policy 025].

Phases of the DBS pathway and the psychotherapist's tasks

1. Consideration and referral. Goal: identify whether a client with severe, refractory illness might be discussed with a specialist DBS centre. Criteria to move on: the treating physician refers; the client wants an evaluation. Your task: psychoeducation, no promises, route to the physician [synthesis].
2. Multidisciplinary candidate evaluation. Goal: confirm diagnosis, refractoriness, severity, medical suitability, psychiatric stability and psychosocial supports. Mayo Clinic describes medical tests, brain imaging and a risk-benefit discussion; for Tourette, the AAN recommends a multidisciplinary screening team, screening for functional tics, and psychiatric assessment before and after surgery; the 2006 TAA guideline required stabilised psychiatric comorbidity and no active suicidal or homicidal ideation for six months; psychosocial factors (stable supportive environment) and psychological factors (resilience, coping) are considered [source: Mayo Clinic; Xu et al. 2020]. In the Amsterdam OCD research programme, candidates had to have responded insufficiently to at least 16 sessions of CBT, among other treatments [source: Mantione et al. 2015]. Criteria to move on: the team's decision and the client's informed consent.
3. Surgery. Two stages: lead implantation (often with the person awake so effects can be tested; sometimes under general anaesthesia) and placement of the pulse generator in the chest under general anaesthesia [source: Mayo Clinic]. Your task: pre-surgical anxiety support and practical planning [synthesis].
4. Activation and optimisation. The generator is usually switched on a few weeks after surgery; finding the best settings can take four to six months (Mayo Clinic) or several months (Medtronic OCD page). Your task: close monitoring of mood and behaviour, liaison with the team, family support. Criteria to move on: symptom stabilisation as judged by the team.
5. Integration and maintenance. Ongoing programming visits, battery replacement when needed (outpatient procedure; rechargeable devices exist), hardware checks [source: Mayo Clinic; Medtronic; Xu et al. 2020]. Your task: integrating psychotherapy (for OCD, CBT/ERP once symptoms have stopped declining, as in Mantione et al. 2014), adjustment and identity work, relapse prevention.
6. Long-term follow-up, non-response, device problems, or research-trial end. Your task: support through disappointment, decisions about continuing, sudden loss of benefit, and transitions [synthesis].

Session count and format for the psychotherapist are not specified by any source opened. A workable pattern [synthesis]: 2 to 4 sessions around evaluation and consent; 1 to 2 before surgery; weekly or fortnightly contact during the first months of optimisation; then the client's ongoing therapy, with ERP or other structured work as indicated (Mantione et al. 2014 used a standardised 24-week CBT programme after stabilisation).

3. Guiding principles

• The team treats the device; you treat the person. Never comment on settings, targets or programming; route every device question to the team [synthesis].
• DBS is not a cure. Keep this phrase central in every expectations conversation [source: Mayo Clinic; Medtronic].
• Status differs by indication. Say plainly which uses are approved, which are humanitarian (OCD: effectiveness not demonstrated) and which are investigational (depression) [source: Medtronic ISI; Abbott].
• Psychiatric effects are expected, not shameful. The labelling says DBS may cause new or worsening psychiatric symptoms; normalise reporting them [source: Medtronic ISI; Cyron 2016].
• Hypomania may feel good to the client and look worrying to the family. Ask relatives as well as the client, with consent [source: Cyron 2016].
• Suicide risk is monitored actively after implantation. Depression, suicidal thoughts and suicide have been reported; build a safety plan before surgery [source: Medtronic ISI; Cyron 2016 citing Voon et al. 2008].
• Families are part of the system. Partners may experience the changes as abrupt personality change; caregiver burden is under-recognised [source: Cyron 2016].
• Informed consent is a process, not a signature. Repeated, unhurried conversations, with the partner where the client wishes, covering psychiatric risks and personality change [source: Cyron 2016].
• Psychotherapy complements, not competes. In OCD, CBT added after stabilisation further reduced symptoms [source: Mantione et al. 2014].
• Never advise on starting, stopping or changing DBS or medicines. Explore ambivalence; the decision belongs with the client and the team [synthesis].
• Fast, consented information flow. Agree in writing what you will pass to the team and how quickly [synthesis].
• Name uncertainty honestly. Long-term psychiatric safety is not definitively established, according to Cyron (2016) [source: Cyron 2016].

4. Intervention inventory

Part A describes how the treating team delivers DBS, at a descriptive level only, so you can explain it accurately. Part B is the psychotherapist's own work.

A1. Multidisciplinary candidate selection (delivered by the DBS team)

• Purpose: decide whether DBS is appropriate and safe for this person.
• What happens: medical tests and brain imaging; a structured discussion of risks and expected benefit with the team [source: Mayo Clinic]. For Tourette syndrome, selection rests on refractoriness and severity (self-injurious or life-threatening tics are cited), a case-by-case judgement rather than a fixed age limit since the 2015 TAA update, stabilised psychiatric comorbidity, no active suicidal or homicidal ideation for six months (2006 TAA), a stable supportive social environment, and psychiatric assessment before and after surgery by a multidisciplinary team (AAN) [source: Xu et al. 2020]. For OCD under the US HDE, the person must be an adult with chronic, severe, treatment-resistant OCD who has failed at least three SSRIs [source: Medtronic ISI]. Research protocols set further criteria, e.g. at least 16 CBT sessions without sufficient response [source: Mantione et al. 2015], or, for depression trials, failure of at least four types of antidepressant treatment and age 22 to 70 [source: Abbott 2024].
• Watch for: clients who believe a team decision is a judgement of their worth; clients minimising symptoms or suicidality to be accepted [synthesis].

A2. Surgery (delivered by functional neurosurgery)

• What happens: a stereotactic frame holds the head still while imaging guides lead placement; leads are often placed with the person awake so effects can be tested, with local anaesthetic to the scalp, or under general anaesthesia; one or both sides may be implanted. In a second procedure under general anaesthesia the pulse generator is placed under the skin near the collarbone and connected [source: Mayo Clinic].
• Surgical risks the sources list: misplaced leads, brain bleeding, stroke, infection, breathing problems, nausea, heart problems and seizures [source: Mayo Clinic]; Medtronic's OCD labelling adds coma and states that some complications may be fatal [source: Medtronic OCD risks page].

A3. Activation, programming and adaptive DBS (delivered by the programming clinician)

• What happens: the generator is usually switched on a few weeks after surgery and adjusted over repeated visits; reaching the best effect can take four to six months; the person has a hand-held controller, and depending on the plan stimulation may run continuously or be switched off at night [source: Mayo Clinic]. Many stimulation side effects can be managed by adjusting settings [source: Medtronic OCD risks page].
• Adaptive DBS: BrainSense Adaptive (Medtronic, FDA approval announced 24 February 2025, Parkinson's disease) senses and classifies brain signals and adjusts stimulation automatically to the person's changing needs; investigators described possible benefit for people with motor fluctuations, dyskinesias or side effects on continuous DBS [source: AJMC 2025]. What this means psychologically is not described in the sources [uncertain]; clients may have questions about a device that reads brain signals (privacy, feeling monitored) [synthesis].

A4. Official safety information to know (from labelling and patient information)

• Psychiatric and behavioural: DBS may cause new or worsening neurological or psychiatric symptoms; depression, suicidal thoughts and suicide have been reported; monitor for depression, anxiety and hypomania or mania, with signs including changes in sleep or eating, disinhibition, anger, aggression and a tendency to accidents [source: Medtronic OCD ISI and risks page]. Mayo Clinic lists mood changes including anger, mania and depression among stimulation side effects, often improving with adjustment [source: Mayo Clinic].
• From the literature: early hypomania may be under-recognised, may inflate mood and quality-of-life scores, and can distress families even when the patient feels well; depression and apathy may emerge later and persist; some patients show lasting risk-seeking, reckless driving, or aggressive or contemptuous behaviour towards relatives; elevated suicide rates were reported in some studies (Voon et al. 2008), not confirmed in one short prospective trial (Weintraub et al. 2013) [source: Cyron 2016, an opinion review]. In Tourette DBS, depression and hypomania (with some targets), and emotional disturbance and apathy (with thalamic DBS), have been reported [source: Xu et al. 2020]. In OCD DBS, cognitive adverse events were mainly mild forgetfulness and word-finding problems in one study [source: Mantione et al. 2015].
• Device: infection, parts wearing through the skin, lead movement, therapy stopping suddenly through mechanical or electrical problems, possibly needing further surgery; if stimulation stops, symptoms are likely to return, and may worsen [source: Medtronic].
• Interactions: implantation is contraindicated for people who will be exposed to diathermy or transcranial magnetic stimulation; the safety of ECT with an implanted DBS system has not been established; MRI only as the labelling describes; electromagnetic interference can cause serious injury [source: Medtronic ISI]. Mayo Clinic advises discussing swimming with a clinician [source: Mayo Clinic].
• Your use: keep this list to recognise and pass on problems; never interpret them yourself as stimulation-related or not [synthesis].

B1. Recognising when to suggest a specialist discussion

• Purpose: help a client with severe, refractory illness learn whether DBS evaluation is relevant, without raising false hope [synthesis].
• Steps: (1) note persistent severe illness despite adequate trials of standard treatments (for OCD, that includes adequate ERP); (2) check that the client's physician or psychiatrist knows the history; (3) suggest the client ask the physician whether a specialist centre opinion is appropriate; (4) for depression, explain that access is through research trials only; (5) record the conversation.
• Example language (illustrative): 'Some people with OCD as severe and long-standing as yours are assessed for a brain surgery treatment called DBS. Whether it is right for you is a question for your psychiatrist and a specialist team. Would you like to raise it with them?'
• Watch for: the client hearing 'last resort' as 'hopeless'; wish to stop therapy while waiting [synthesis].

B2. Psychoeducation about DBS

• Purpose: an accurate, simple shared picture of what DBS is and is not [source for content: Mayo Clinic; Medtronic; Abbott].
• Steps: (1) ask what the client already knows and has read; (2) explain the basics: implanted leads, chest generator, adjustable, can be switched off, not a cure, effect may take months to reach; (3) explain status for their indication (approved, humanitarian with unproven effectiveness, or investigational); (4) name the main risk groups: surgical, device, stimulation-related including mood and behaviour; (5) give the team's own written materials and encourage questions to the team; (6) check understanding with teach-back [synthesis for steps].
• Example language (illustrative): 'The team describes DBS as reducing symptoms rather than curing them, and adjusting it takes months. Can you tell me in your own words what you expect the first half-year to look like?'
• Watch for: magical expectations, catastrophic fears, confusion between approved and trial use.

B3. Expectations work and informed-consent support

• Purpose: support a free, informed and realistic decision; the consent itself is obtained by the treating team.
• Rationale from sources: patients and relatives tend to underestimate pre-operative disability; Cyron recommends full information about psychiatric risks, possible personality change and target options, involving partners and next of kin, and framing DBS as reversible because stimulation can be switched off [source: Cyron 2016]. A systematic review of expectations and outcomes after DBS in Parkinson's exists (Role of expectations in clinical outcomes after DBS in Parkinson's: a systematic review) but is not drawn on [uncertain].
• Steps: (1) elicit hoped-for outcomes in concrete daily-life terms; (2) separate what DBS may change (symptom intensity) from what it will not by itself (relationships, work, habits); (3) list questions to take to the team (risk of mood change, what happens if it does not help, follow-up burden, travel, cost, trial obligations); (4) explore pressure from family or the sense of 'no other option'; (5) rehearse how the client will tell the team about doubts; (6) if you have concerns about capacity or coercion, raise them with the team with consent [synthesis].
• Example language (illustrative): 'If DBS took away about half of the time you spend on rituals, what would you do with those hours? And how would you feel if it helped less than that?'
• Watch for: ambivalence hidden for fear of being rejected; consent driven by a partner's exhaustion.

B4. Contributing to the pre-surgical psychological assessment

• Purpose: give the team the psychological information published selection criteria rely on: psychiatric comorbidity and its stability, suicidality history, coping and resilience, and the social environment [source: Xu et al. 2020].
• Steps: (1) obtain written consent to share; (2) provide a factual summary: diagnoses, course, treatments tried in therapy including number and type of CBT/ERP sessions (research protocols may require this, as in Mantione et al. 2015), engagement, suicidality history and current risk, substance use, supports; (3) state what you do not know; (4) do not offer a candidacy opinion unless asked; formal psychiatric and neuropsychological testing is done by the team's specialists. A social-work screening tool (DBS-FACTS) for the pre-operative evaluation has been published but is not drawn on [uncertain].
• Example language (illustrative, to the client): 'The team will ask about your mood and any suicidal thoughts over recent months. Being honest helps them keep you safe; it is not a test you pass or fail.'
• Watch for: pressure on you to advocate; client concealing risk.

B5. Preparing for surgery and the first months

• Purpose: reduce anticipatory anxiety and set up the support structure before the high-risk period [synthesis].
• Steps: (1) use the team's own description of the procedure (e.g. awake lead placement, two stages) to identify specific fears; (2) teach a brief coping skill the client can use during waiting and procedures (paced breathing, grounding); (3) plan practicalities: who accompanies them, travel to programming visits, time off; (4) agree the monitoring and information-sharing plan (B6) and safety plan (B7) before surgery, while the client is at baseline; (5) arrange session frequency for the optimisation months.
• Example language (illustrative): 'Before the operation, let's write down together who notices what, and who they tell, in case your mood shifts during the adjustment months.'
• Watch for: avoidance of planning ('it will be fine').

B6. Monitoring mood and behaviour after implantation and passing it on

• Purpose: early detection of the psychiatric and behavioural effects the labelling and literature describe: depression, suicidal thoughts, anxiety, hypomania or mania, disinhibition, anger, aggression, accident-proneness, impulsivity and risk-taking, apathy, sleep and appetite change [source: Medtronic risks page; Cyron 2016; Xu et al. 2020].
• Steps: (1) at baseline, record the client's usual mood, sleep, appetite, spending, driving and irritability, and ask a partner (with consent) to describe the client's usual self; (2) after activation and each programming change the team reports, check these at each session; brief validated mood measures can be used [synthesis]; (3) ask the partner too, since hypomania may feel good to the client while worrying relatives [source: Cyron 2016]; (4) agree thresholds for contacting the team the same day (suicidal thoughts, manic signs, aggression, dangerous risk-taking) versus at the next visit; (5) pass on observations factually (what, since when, who noticed), not interpretations about settings; (6) record what you passed on and when.
• Example language (illustrative): 'You say you feel better than in years, which is great to hear. Your partner mentioned you have hardly slept this week and bought a car on impulse. The team asks to know about changes like that; shall we call them together now?'
• Watch for: changes appearing weeks to months after activation; later-emerging apathy or depression after an early lift [source: Cyron 2016]. It is working when changes are reported early and the client experiences reporting as collaborative.

B7. Suicide risk assessment and crisis planning

• Purpose: depression, suicidal thoughts and suicide have been reported after DBS, including under close monitoring [source: Medtronic ISI; Cyron 2016 citing Voon et al. 2008 and Schuepbach et al. 2013].
• Steps: (1) complete standard suicide risk assessment before surgery and repeat regularly after activation, especially after programming changes, disappointing results, or abrupt loss of benefit; (2) write a collaborative safety plan: warning signs, internal coping, people and places, professional contacts including the DBS team's urgent number and local crisis services, lethal-means counselling (safe storage or removal); (3) add device-specific items: what to do if the device seems to stop working or symptoms suddenly return (contact the team; labelling notes therapy may stop suddenly and symptoms return or worsen) [source: Medtronic]; (4) share the plan, with consent, with the family and team; (5) escalate per your usual emergency procedures when risk is high [synthesis for steps].
• Example language (illustrative): 'If the device ever stops and the old symptoms come back fast, that can be frightening. Your plan says you call the DBS clinic first and me second. Who would drive you if needed?'
• Watch for: hopelessness after non-response; risk rising while mood seems elevated.

B8. Identity, personality and adjustment work

• Purpose: help the client make sense of changes in self-experience and life roles after DBS.
• Rationale from sources: relatives often describe sudden personality changes that come as a shock; DBS may restore a former personality that no longer fits current family life; changes in moral reasoning and consideration for others may be hard to measure by self-report; identity after DBS has been studied (Witt et al. 2013, cited by Cyron); marital conflict has been reported (Schupbach et al. 2006, cited by Cyron) [source: Cyron 2016]. Clinical trials of psychoeducational support for psychosocial maladjustment after subthalamic DBS in Parkinson's exist (e.g. the trial titled Tackling psychosocial maladjustment in Parkinson's disease patients following subthalamic deep-brain stimulation; NCT02554370), but they are not drawn on, so their content is not described here [uncertain].
• Steps: (1) invite the client's narrative of before and after; (2) distinguish (without settling causes) symptom relief, recovered capacities, and new traits others notice; (3) explore loss of the illness role, of carer relationships organised around symptoms, and grief for years lost; (4) set new value-based goals for freed time and energy (work, relationships, activities); (5) where traits concern others (irritability, contempt, risk-taking), pass on to the team per B6 rather than treating them only as personality [synthesis for steps].
• Example language (illustrative): 'Some people say after DBS that they are more themselves, others that they hardly recognise themselves, and families can see it differently again. What is it like for you?'
• Watch for: unexpected sadness despite symptom relief; family conflict about who the person is now.

B9. Family and caregiver support

• Purpose: caregiver burden after DBS has received little attention; seminars for patients and spouses on post-DBS conflicts have been offered [source: Cyron 2016 citing Lewis et al. 2015].
• Steps: (1) with consent, offer joint sessions before surgery and during optimisation; (2) give the family the monitoring list and how to contact the team; (3) work on role renegotiation as care needs change; (4) refer relatives for their own support when needed [synthesis].
• Example language (illustrative, to a partner): 'You have been his carer for years. If he needs you less now, that can be a relief and also unsettling. Both are normal.'
• Watch for: partner being the only one who sees warning signs, and not being believed.

B10. Integrating psychotherapy after implantation: ERP for OCD

• Purpose: DBS for OCD typically gives partial response; in Mantione et al. (2014), a standardised 24-week CBT programme added after symptoms stopped declining with DBS produced a further significant decrease in obsessive-compulsive symptoms (not in anxiety or depression); the authors suggest DBS produces affective changes that may be needed to enable response prevention, and that the two treatments may be complementary [source: Mantione et al. 2014 abstract]. Session content of that programme was not available in the source opened [uncertain].
• Steps (standard ERP, adapted [synthesis]): (1) start or resume when the team considers symptoms stabilised; (2) re-assess current obsessions, compulsions and avoidance, since the pattern may have shifted; (3) psychoeducation about ERP and consent to exposure, including the right to pace or stop; (4) build an exposure hierarchy with the client; (5) carry out graded exposures with response prevention in session and as homework; (6) cognitive work on threat and responsibility beliefs as needed; (7) relapse-prevention plan including what to do if the device fails and symptoms return; (8) share progress with the team, with consent.
• Contraindications and safety for exposure [synthesis]: postpone or adapt during acute post-operative recovery, wound or hardware problems, hypomania or severe depression, or active suicidality; avoid exposures involving physical risk to the implant site; coordinate timing with programming visits.
• Example language (illustrative): 'The stimulation seems to have turned down the volume on the anxiety. ERP is how we teach your brain that you can face the trigger and not do the ritual. Shall we pick the first step together?'
• Watch for: new willingness to try exposures (a good sign); reliance on the device as a safety behaviour ('I can do it only because it is on').

B11. Psychotherapy for other indications

Purpose: to continue or start evidence-based psychological treatment for the client's own indication alongside DBS, coordinated with the team [synthesis].

• Tourette syndrome: the AAN recommends offering cognitive behavioural therapy, and psychiatric assessment before and after surgery [source: Xu et al. 2020]; behavioural tic therapy (e.g. comprehensive behavioural intervention for tics) and therapy for co-occurring OCD, ADHD or mood problems can continue alongside DBS [synthesis].
• Parkinson's disease and tremor: evidence-based therapy for depression, anxiety and apathy, with attention to driving, finances and relationships if impulsivity emerges [synthesis].
• Depression trials: support the participant through blinding and possible sham periods, and plan for trial end; keep usual safety planning [synthesis].
• Example language (illustrative): "The stimulator works on some symptoms; our sessions work on the habits, worries and relationships around them. Shall we pick up where we left off?"
• Watch for: new impulsivity, mood elevation or apathy that gets in the way of therapy, which goes to the team (B6). Working if therapy goals progress alongside device follow-up [synthesis].

B12. Adherence and ambivalence conversations

• Purpose: clients may skip programming visits, wish to switch the device off, or feel ambivalent about remaining in a trial; explore without advising [synthesis].
• Steps: (1) reflect both sides of the ambivalence; (2) explore the meaning (side effects, disappointment, identity, burden of visits); (3) encourage the client to bring it to the team; (4) offer to help them prepare or to attend jointly; (5) if safety is at stake, follow B7.
• Example language (illustrative): 'Part of you wants to switch it off, part of you is scared of the old symptoms coming back. That decision belongs with you and the team. What would you want them to know?'
• Watch for: unilateral decisions made in crisis.

B13. Long-term follow-up and endings

• Purpose: support through battery replacement, hardware revision, non-response, decisions to remove the system, or the end of a trial [synthesis; source for facts: Mayo Clinic; Medtronic].
• Steps: (1) mark procedures in the treatment plan and plan for transient symptom return around them; (2) process grief or anger if DBS did not help; (3) update the safety plan; (4) agree how therapy continues or ends, and who the client contacts later.
• Example language (illustrative): "When the battery change is due, some symptoms may come back for a while. Let's plan now what you'll do and who you'll call."
• Watch for: grief or anger turning into hopelessness, or the client dropping out of team follow-up. Working if the client knows how to get back in touch and the safety plan is current [synthesis].

5. Handling problems

All responses below are [synthesis] unless a source is tagged.

• Client feels great, family alarmed (possible hypomania). Hypomania can feel good to the client while distressing relatives, and may impair judgement [source: Cyron 2016]. Response: validate the relief, name the specific observed changes (sleep, spending, driving, irritability), remind the client of the plan agreed before surgery, and contact the team the same day with consent; if the client refuses and safety is at risk, follow your duty-of-care procedures.
• Disappointment or partial response. DBS is not a cure and optimisation takes months [source: Mayo Clinic]. Response: revisit baseline expectations, look at function rather than symptom scores only, screen for depression and suicidality, and consider adding structured therapy (e.g. ERP for OCD, per Mantione et al. 2014).
• 'Burden of normality': distress despite symptom relief. Response: work on loss of the illness role, new roles and goals (B8); involve the partner if roles have shifted. The concept is described in DBS literature, but the sources describing it are not drawn on [uncertain].
• Sudden return of symptoms. Therapy may stop through mechanical or electrical problems or battery depletion [source: Medtronic]. Response: urge immediate contact with the DBS team, activate the safety plan, and avoid interpreting the cause yourself.
• Client wants to switch off or leave a trial. Response: explore ambivalence (B12), never advise; encourage a discussion with the team, which can plan for symptom return (symptoms are likely to return when stimulation stops [source: Medtronic]).
• Avoidance of exposure after DBS (OCD). Response: re-check the rationale, start lower on the hierarchy, address beliefs that the device must do all the work, and check for depression or apathy that may reduce engagement.
• New impulsivity, aggression or risk-taking. Reported after subthalamic DBS in Parkinson's [source: Cyron 2016]. Response: report to the team promptly; meanwhile help the client and family with protective steps (pausing big financial decisions, driving safety discussion with the physician); do not frame it only as a relationship problem.
• Client concealing suicidality or symptoms to be accepted as a candidate. Response: explain that published selection asks about recent suicidality for safety reasons [source: Xu et al. 2020]; keep risk assessment honest; discuss the importance of transparency; never collude.
• Questions about other treatments. TMS and diathermy are contraindicated with the OCD system, ECT safety with DBS is not established, and MRI is allowed only as labelling describes [source: Medtronic ISI]. Response: route all such questions to the DBS team before any other neuromodulation is considered.
• Seeking DBS for depression outside a trial. It is investigational [source: Abbott 2024]. Response: explain the status; if interested, the client's psychiatrist can advise on registered trials; continue evidence-based treatment meanwhile.
• Cognitive complaints (forgetfulness, word-finding). Reported as mostly mild in an OCD study [source: Mantione et al. 2015]. Response: pass on to the team; adapt therapy with written summaries and shorter tasks.
• Disagreement between you and the team. Response: raise concerns directly, document, and keep the client's trust by avoiding triangulation; agree a single route for clinical decisions.
• Rupture after you passed on information the client did not want shared. Response: acknowledge, return to the written information-sharing agreement made before surgery, and repair; if the agreement was unclear, renegotiate it.
• Confidentiality and trial data. Response: clarify which information goes to the treating team versus the research team, with written consent.
• Family exhaustion or caregiver burnout. Response: offer joint sessions and referrals for relatives' own support [source for context: Cyron 2016].

Sources

• Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease (AJMC, 26 Feb 2025)
• FDA HDE database record, RECLAIM DBS for OCD Therapy, H050003 (supplement S061)
• Medtronic: Reclaim DBS for OCD, Important Safety Information (Rev 02/22)
• Medtronic: DBS for OCD, Risks and probable benefits
• [Mayo Clinic: Deep brain stimulation](https://www.mayoclinic.org/tests-procedures/deep brain-stimulation/about/pac-20384562)
• BSW Health Plan Medical Coverage Policy 025: Deep Brain Stimulation (effective 03/01/2025)
• Abbott: Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression (4 Sep 2024)
• Xu W, Zhang C, Deeb W, et al. (2020). Deep brain stimulation for Tourette's syndrome. Translational Neurodegeneration 9:4
• Mantione M, Nieman DH, Figee M, Denys D (2014). Cognitive-behavioural therapy augments the effects of deep brain stimulation in obsessive-compulsive disorder. Psychological Medicine 44(16):3515-3522 (abstract)
• Mantione M, Nieman D, Figee M, et al. (2015). Cognitive effects of deep brain stimulation in patients with obsessive-compulsive disorder. Journal of Psychiatry and Neuroscience 40:378-386
• Cyron D (2016). Mental side effects of deep brain stimulation (DBS) for movement disorders: the futility of denial. Frontiers in Integrative Neuroscience 10:17
• Further reading (not drawn on), cited only as reported in the sources above: Voon et al. (2008); Weintraub et al. (2013); Schuepbach et al. (2013); Schupbach et al. (2006); Witt et al. (2013); Lewis et al. (2015) [uncertain].
• Further reading (not drawn on): psychoeducational programme trial for Parkinson's patients with subthalamic DBS (NCT02554370) and the related randomised trial on psychosocial maladjustment; DBS-FACTS social-work screening tool; expectations systematic review [uncertain].